Free Trial

Protara Therapeutics (TARA) Competitors

Protara Therapeutics logo
$5.49 -0.29 (-5.02%)
Closing price 04:00 PM Eastern
Extended Trading
$5.60 +0.11 (+1.91%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TARA vs. OLMA, AKBA, ORKA, TYRA, PVLA, TBPH, TERN, NRIX, GYRE, and ARVN

Should you be buying Protara Therapeutics stock or one of its competitors? The main competitors of Protara Therapeutics include Olema Pharmaceuticals (OLMA), Akebia Therapeutics (AKBA), Oruka Therapeutics (ORKA), Tyra Biosciences (TYRA), Palvella Therapeutics (PVLA), Theravance Biopharma (TBPH), Terns Pharmaceuticals (TERN), Nurix Therapeutics (NRIX), Gyre Therapeutics (GYRE), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry.

Protara Therapeutics vs. Its Competitors

Protara Therapeutics (NASDAQ:TARA) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

38.1% of Protara Therapeutics shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 8.4% of Protara Therapeutics shares are owned by insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Protara Therapeutics. MarketBeat recorded 2 mentions for Olema Pharmaceuticals and 0 mentions for Protara Therapeutics. Olema Pharmaceuticals' average media sentiment score of 0.57 beat Protara Therapeutics' score of 0.00 indicating that Olema Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Protara Therapeutics Neutral
Olema Pharmaceuticals Positive

Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protara TherapeuticsN/AN/A-$44.60M-$1.62-3.39
Olema PharmaceuticalsN/AN/A-$129.47M-$1.98-4.73

Protara Therapeutics presently has a consensus target price of $19.60, indicating a potential upside of 257.01%. Olema Pharmaceuticals has a consensus target price of $23.33, indicating a potential upside of 149.29%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protara Therapeutics is more favorable than Olema Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protara Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Olema Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63

Protara Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500.

Protara Therapeutics' return on equity of -36.87% beat Olema Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Protara TherapeuticsN/A -36.87% -33.85%
Olema Pharmaceuticals N/A -42.58%-38.65%

Summary

Protara Therapeutics beats Olema Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Get Protara Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TARA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TARA vs. The Competition

MetricProtara TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$223M$2.64B$6.11B$10.51B
Dividend YieldN/A57.79%5.73%4.81%
P/E Ratio-3.3922.9984.5227.09
Price / SalesN/A761.85609.45131.82
Price / CashN/A168.7137.1661.22
Price / Book1.155.3212.246.52
Net Income-$44.60M$33.06M$3.32B$276.75M
7 Day Performance5.17%-0.81%0.76%0.92%
1 Month Performance81.19%9.20%8.03%4.20%
1 Year Performance196.76%-3.82%71.13%37.86%

Protara Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TARA
Protara Therapeutics
1.838 of 5 stars
$5.49
-5.0%
$19.60
+257.0%
+210.8%$223MN/A-3.3930
OLMA
Olema Pharmaceuticals
2.9862 of 5 stars
$11.06
-0.4%
$24.00
+117.0%
-22.0%$761.84MN/A-5.5970Gap Down
AKBA
Akebia Therapeutics
3.4349 of 5 stars
$2.97
+4.9%
$6.75
+127.3%
+119.5%$750.36M$160.18M-17.47430
ORKA
Oruka Therapeutics
2.7887 of 5 stars
$20.33
+2.7%
$42.00
+106.6%
-8.4%$741.15MN/A-7.23N/A
TYRA
Tyra Biosciences
2.4771 of 5 stars
$13.43
-1.7%
$31.86
+137.2%
-42.7%$728.04MN/A-7.5420High Trading Volume
PVLA
Palvella Therapeutics
1.7344 of 5 stars
$67.95
+3.3%
$69.27
+1.9%
N/A$727.51M$42.81M-5.62N/AShort Interest ↑
TBPH
Theravance Biopharma
3.2343 of 5 stars
$14.58
+1.2%
$23.00
+57.8%
+61.4%$725.70M$77.21M60.75110News Coverage
Gap Up
TERN
Terns Pharmaceuticals
4.0791 of 5 stars
$8.43
+2.4%
$15.49
+83.7%
+12.5%$720.22MN/A-8.1140News Coverage
Analyst Forecast
NRIX
Nurix Therapeutics
1.8622 of 5 stars
$9.95
+6.1%
$29.07
+192.2%
-61.1%$717.09M$54.55M-3.81300Trending News
Analyst Forecast
Analyst Revision
GYRE
Gyre Therapeutics
1.2804 of 5 stars
$7.34
-0.9%
$18.00
+145.2%
-37.5%$713.68M$105.76M734.7340News Coverage
ARVN
Arvinas
3.5372 of 5 stars
$9.62
+0.1%
$16.18
+68.2%
-65.2%$705.54M$263.40M-9.52420Analyst Downgrade
Gap Down

Related Companies and Tools


This page (NASDAQ:TARA) was last updated on 10/17/2025 by MarketBeat.com Staff
From Our Partners